1-(difluoromethyl)-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole → 1-(6-(1,4-Diazepan-1-yl)pyridin-2-yl)-6-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridine

Participants

Reaction Steps

Following the procedures as described in Example 45 and starting with tert-butyl 4-(6-(6-chloro-1H-pyrazolo[4,3-c]pyridin-1-yl)pyridin-2-yl)-1,4-diazepane-1-carboxylate and 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, 173 was obtained as a white solid (80 mg, 35%) over three steps. 1H-NMR (500 MHz, CD3OD) δ (ppm) 9.06 (s, 1H), 8.73 (s, 1H), 8.50 (s, 1H), 8.34 (s, 1H), 8.15 (s, 1H), 7.50-7.67 (m, 2H), 7.23 (d, J=7.5 Hz, 1H), 6.58 (d, J=8.0 Hz, 1H), 3.87-3.90 (m, 4H), 3.13-3.15 (m, 2H), 2.91-2.94 (m, 2H), 2.03-2.08 (m, 2H); MS (ESI) m/z: 411 [M+H]+.

Provenance & Evidence